Vyvgart Hytrulo CIDP denied as not medically necessary by Blue Cross Blue Shield?

Blue Cross Blue Shield's specific coverage criteria for vyvgart hytrulo cidp are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why BCBS Denies Vyvgart Hytrulo for CIDP on Medical-Necessity Grounds

Chronic inflammatory demyelinating polyneuropathy (CIDP) is a serious autoimmune nerve disorder, and Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc, subcutaneous formulation) carries FDA approval specifically for adults with CIDP. Despite that approval, Blue Cross Blue Shield plans routinely issue medical-necessity denials when submitted documentation does not clearly map the patient's clinical picture to every criterion in the plan's coverage policy. This is a well-established, highly appealable denial type.

## Why This Denial Is Appealable

An FDA approval for the exact indication you are treating is one of the strongest possible foundations for a medical-necessity appeal. BCBS must demonstrate that its criteria are grounded in sound clinical evidence and recognized standards of care. If your prescriber can document that the patient meets the eligibility requirements described in both the FDA-approved prescribing information and the applicable neurology society guidelines, the denial lacks a defensible clinical basis.

## Federal Appeal Framework

• Internal appeal: Under ACA §2719 and ERISA §503, you are entitled to a full-and-fair internal review. Submit within the plan's stated deadline (commonly 180 days from the denial notice — verify your specific Explanation of Benefits).
• External review: If the internal appeal is denied, you have the right to an independent external review. The external-review request window is typically around four months from the final internal denial, though your plan documents control the exact deadline.
• Expedited review: If the standard timeline would seriously jeopardize the patient's health, request expedited internal and external review simultaneously.

## Appeal Timeline (Typical)

| Stage | Insurer Deadline | |---|---| | Internal appeal decision | 30 days (pre-service) / 60 days (post-service) | | External review decision | 45 days standard / 72 hours expedited |

## Documentation to Gather

1. Confirmed CIDP diagnosis — neurology notes, nerve conduction study results, and any supporting electrodiagnostic findings establishing diagnosis per current guideline criteria. 2. Prior treatment history — dates, agents used, duration, and documented outcomes (response, intolerance, or contraindication) for every therapy the plan may require as a prerequisite. 3. Current functional severity — chart documentation of disability scale scores, grip strength, ambulation status, or other objective measures your neurologist uses. 4. Prescriber medical-necessity letter — a detailed letter explaining why Vyvgart Hytrulo is the appropriate therapy for this patient, referencing the FDA label indication and the applicable neurology guideline organization (such as the relevant peripheral nerve society guidelines). 5. BCBS coverage policy — download the plan's current medical policy for this drug and attach it to your appeal so reviewers see you are addressing each criterion directly.

## Criteria-Mapping Structure

Create a table with three columns: (1) each requirement listed in the BCBS medical policy, (2) the corresponding requirement in the FDA prescribing label, and (3) the specific chart evidence satisfying that requirement. Reviewers respond well to this format because it removes ambiguity. Obtain the exact eligibility thresholds and any required diagnostic criteria from the FDA label and the insurer's published policy — do not rely on third-party summaries, as thresholds change with policy updates.